

brief follow-up note

date: nov 30, 2023

pt: mcdonalds, jennifer l ("jen") dob jan 25, 1973 (mrn: SYN104)

provider: v. wells, md

interval hx: pt seen for routine f/u, on alectinib 600mg bid since july 2023 for stage iv alk+ lung adeno (dx june 2023, mets to bone). pdl1 tps 50%.

status: doing extremely well. asymptomatic. ecog 0. tolerating alectinib w/ only gr 1 dry skin. bone pain resolved. adherent. receiving zoledronic acid q3mos.

objective: exam wnl. labs wnl (cbc/cmp/lfts/cpk). ct c/a/p (nov 20, 2023): pr ongoing, bone lesions sclerotic/stable. brain mri neg.

assessment/plan: excellent response/tolerance to alectinib + za. continue current regimen. labs/f-u in 3 mos. next scans ~feb 2024. cont ca/d. rtc sooner prn.